Journal of Immunotherapy · 2001 · 13 citations · 21 references
MedicineImmunologyOncologyAntibody EngineeringCancer ImmunologyTumor ImmunologyAntibody-antigen RecognitionAntitumor T Cell ResponsesCancer ImmunotherapyImmunotherapy For Breast CancerT Cell Responses To TumorsTumor-associated AntigensAdaptive Antitumor ImmunityCostimulatory Signal TransductionMonoclonal Antibodies In OncologyReceptorsSignal Transduction In T CellsT Cell Costimulatory PathwaysTumor Antigen-based ImmunotherapyTumor-specific T Cell Activation
The provision of the T-cell costimulatory molecule B7 to tumor cells can be an effective way to trigger a tumor-specific cytolytic T-cell response. One way to provide B7 to tumor cells would be to couple an antitumor antibody directly to B7. Such a molecule should target tumors displaying antigen and provide the costimulatory signal to T cells, resulting in the initiation of an antitumor T-cell response. To this end, a fusion protein was designed that incorporates a single-chain antibody fragment (scFv) to erbB-2 (Her2/neu), an oncogene product overexpressed by 30% to 50% of breast carcinomas, and the ECD of B7-2 (CD86). This fusion protein, expressed and purified from Pichia pastoris, was shown to retain binding activity to both counter receptors, erbB-2 and CD28. The fusion protein was also shown to target erbB-2-positive tumor cells and to deliver a CD28-specific T-cell costimulatory signal. These results suggest that a fusion protein engineered to target tumor cells and signal T cells for activation may be an effective means of cancer immunotherapy. Further studies should be performed to characterize the fusion protein in erbB-2 tumor-bearing mice for in vivo tumor targeting, biodistribution, and efficacy.
21
Studies of the HER-2/ <i>neu</i> Proto-Oncogene in Human Breast and Ovarian Cancer
Dennis J. Slamon, William Godolphin, Lovell A. Jones et al. · Science · 1989 · 6.9K citations
A Cell Culture Model for T Lymphocyte Clonal Anergy
Ronald H. Schwartz · Science · 1990 · 1.9K citations